Tarsus Pharmaceuticals In... (TARS)
NASDAQ: TARS
· Real-Time Price · USD
42.92
-0.52 (-1.20%)
At close: May 30, 2025, 3:59 PM
44.40
3.45%
After-hours: May 30, 2025, 05:54 PM EDT
-1.20% (1D)
| Bid | 41 |
| Market Cap | 1.8B |
| Revenue (ttm) | 233.67M |
| Net Income (ttm) | -104.94M |
| EPS (ttm) | -2.7 |
| PE Ratio (ttm) | -15.9 |
| Forward PE | 23.82 |
| Analyst | Buy |
| Ask | 46 |
| Volume | 270,732 |
| Avg. Volume (20D) | 688,888 |
| Open | 43.52 |
| Previous Close | 43.44 |
| Day's Range | 42.04 - 43.52 |
| 52-Week Range | 20.08 - 57.28 |
| Beta | 0.94 |
About TARS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TARS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TARS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-5.84%
Tarsus Pharmaceuticals shares are trading lower fo...
Unlock content with
Pro Subscription
3 months ago
-9.33%
Shares of Tarsus Pharmaceuticals are trading lower. The company reported Q4 financial results.
2 weeks ago · seekingalpha.com
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay OffTARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demo...
1 month ago · seekingalpha.com
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call TranscriptTarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Office...
